Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will list (a) the criteria and (b) the timelines for products to be considered in (i) the current and (ii) future review rounds of the Accelerated Access Collaborative.

In October 2018, the Accelerated Access Collaborative (AAC) announced it was supporting the uptake of 12 high performing products, with the potential to improve the lives of up to 500,000 patients per year and save the National Health Service £30 million per year in England. All the products currently being supported by the AAC have been recommended by the National Institute for Health and Care Excellence, and therefore evidence on clinical benefits and cost savings were considered as part of the process.

The AAC board met on 26 June and had a positive discussion about future products and expects to announce further products later this year.

The AAC will consider the following areas of interest when determining which products to support:

- evidence of clinical and cost effectiveness;

- addressing significant unmet need;

- application to large populations or high budget impact; and

- enabling a novel mode of action or enabling significant changes to the care pathway.